CLEVER HANDELN

Richten Sie Börsennews.de als Startseite ein

Hier klicken

PAM

Der börsennews.de Newsüberblick zum Thema "PAM"

TR ONE-News: Addex to Present at the BIO Investor Forum in San Francisco

07:02 Uhr 24.10.2011

... or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals Inc. to treat schizophrenia. Addex also is advancing several preclinical programs including:... weiter lesen

Addex to Present at the BIO Investor Forum in San Francisco

07:01 Uhr 24.10.2011

... or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals Inc. to treat schizophrenia. Addex also is advancing several preclinical programs including:... weiter lesen

DJ Thomson Reuters ONE/Addex to Present at the BIO Investor Forum in San Francisco

05:01 Uhr 24.10.2011

... or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals Inc. to treat schizophrenia. Addex also is advancing several preclinical programs including:... weiter lesen

DJ Thomson Reuters ONE/Addex to Present at the BIO Investor Forum in San Francisco

05:01 Uhr 24.10.2011

... or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals Inc. to treat schizophrenia. Addex also is advancing several preclinical programs including:... weiter lesen

DJ Thomson Reuters ONE/Addex to Present in NYC at the Newsmakers in the Biotech Industry conference hosted by BioCentury and Thomson Reuters

16:02 Uhr 19.10.2011

... or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals Inc. to treat schizophrenia. Addex also is advancing several preclinical programs including:... weiter lesen

DJ Thomson Reuters ONE/Addex to Present in NYC at the Newsmakers in the Biotech Industry conference hosted by BioCentury and Thomson Reuters

16:02 Uhr 19.10.2011

... or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals Inc. to treat schizophrenia. Addex also is advancing several preclinical programs including:... weiter lesen

DJ Thomson Reuters ONE/Addex to Present Progress on Multiple Allosteric Modulator Programs for Neurodegenerative and other Neurological Disorders

16:02 Uhr 03.10.2011

... reported in the first half of 2012. Addex partner Janssen Pharmaceuticals Inc. is developing ADX71149, an mGluR2 positive allosteric modulator, or PAM, currently in Phase IIa testing for the treatment of schizophrenia. Glutamate, like dopamine and serotonin, is one of the major... weiter lesen

DJ Thomson Reuters ONE/Addex to Present Progress on Multiple Allosteric Modulator Programs for Neurodegenerative and other Neurological Disorders

16:01 Uhr 03.10.2011

... reported in the first half of 2012. Addex partner Janssen Pharmaceuticals Inc. is developing ADX71149, an mGluR2 positive allosteric modulator, or PAM, currently in Phase IIa testing for the treatment of schizophrenia. Glutamate, like dopamine and serotonin, is one of the major... weiter lesen

Addex Regains Rights to Parkinson's Drug Candidates from Merck

18:06 Uhr 02.09.2011

... and development, announced today that it will regain all rights to its metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) program from Merck, known as MSD outside the United States and Canada, due to further pipeline prioritization.   "We continue to... weiter lesen

DJ Thomson Reuters ONE/Addex Regains Rights to Parkinson's Drug Candidates from Merck

16:06 Uhr 02.09.2011

... and development, announced today that it will regain all rights to its metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) program from Merck, known as MSD outside the United States and Canada, due to further pipeline prioritization. "We continue to... weiter lesen

Mehr zu PAM
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. ›
  7. »